Actively Recruiting
Phase 12 Study of Safety and Pharmacokinetics of DT-216P2 Given by Injection in Adults with Friedreichs Ataxia
Led by Design Therapeutics, Inc. · Updated on 2025-05-18
20
Participants Needed
3
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying Friedreichs Ataxia FA, a genetic condition, to assess the safety, tolerability, and how the body processes a drug called DT-216P2. This phase 12 open-label trial focuses on understanding these factors when the drug is given in multiple increasing doses to people with FA. The study is sponsored by Design Therapeutics, Inc. and aims to gather important information about the treatments effects in this patient group. Participants will receive DT-216P2 through subcutaneous under the skin or intravenous into a vein administration in varying doses. The study includes multiple dose levels to observe the drugs behavior and side effects up to 12 weeks. There is no placebo group, and all participants will be treated with DT-216P2 during the study period, which starts in June 2025 and is planned to conclude by March 2027. During the study, participants will be closely monitored for any side effects or adverse events, with particular attention to treatment-emergent adverse events up to week 12. Researchers will also measure drug levels in the body, including maximum concentration and how long it stays in the system. Frataxin protein levels, important in FA, will be checked before and after treatment. Participants will be regularly assessed for safety and treatment effects throughout the study duration.
CONDITIONS
Brief Title
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Research Team
V
Varlli Scott
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here